304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors

A.Lipton; R.J.Cook; P.Major; M.R.Smith; R.E.Coleman

首页> 外文期刊>European Journal of Cancer Supplements >304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors

【24h】

304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors

机译：304口服唑来膦酸使基线骨吸收标记物水平升高的早期正常化，并改善了实体瘤骨转移患者的生存率

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
A.Lipton; R.J.Cook; P.Major; M.R.Smith; R.E.Coleman;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. [J] . Lipton A, Cook R, Saad F, Cancer: A Journal of the American Cancer Society . 2008,第1期

机译：骨标记物的正常化与实体瘤骨转移患者的生存率提高和接受唑来膦酸的骨吸收升高有关。
2. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer [J] . J.F. Hilton, M. Clemons, G. Pond, Journal of Bone Oncology . 2018,第1期

机译：乳腺癌患者高风险骨转移对持续帕米膦酸或转换为唑来膦酸对骨吸收标志物的影响
3. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. [J] . Zhao YY, Xue C, Hou X, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2011,第6期

机译：鼻咽癌伴骨转移的患者化疗联合唑来膦酸的骨吸收标志物（NTX）的变化与单独化疗相比。
4. Radium-223 Dichloride Monotherapy and Combination Therapy with Zoledronic Acid or Doxorubicin Improve Survival in a Mouse Model of Breast Cancer Bone Metastasis [C] . Jukka Rissanen, Mari Suominen, Rami K?k?nen, Molecular Medicine TRI-CON. . 2014

机译：镭-223二氯化物单疗法和组合治疗唑醇或多柔比星改善了乳腺癌骨转移的小鼠模型中的存活
5. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer [O] . J.F. Hilton, M. Clemons, G. Pond, 2018

机译：乳腺癌患者高风险骨转移对持续帕米膦酸或转换为唑来膦酸对骨吸收标志物的影响
6. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid [O] . Allan Lipton, Richard Cook, Fred Saad, 2008

机译：骨标记的标准化与来自实体肿瘤的骨转移和骨吸收升高的骨转移患者的存活率有关，接受唑醇

304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors

著录项

相似文献

相关主题

期刊订阅